Plain-English translation of NCT05798117 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial studied , a type of cell therapy designed to treat people with severe lupus (a serious autoimmune disease) whose condition had not improved despite trying multiple standard treatments. The trial looked at whether the medication was safe, how well it worked, and how the body's immune cells responded to it. Researchers enrolled 21 participants to test this new approach.
Many people with severe lupus do not respond well enough to the medicines currently available, and their disease continues to damage their organs and cause serious symptoms. This trial was designed to see if this new cell-based treatment could help patients whose lupus had resisted other therapies.
Participants in this trial received a single infusion of , the experimental medication being tested. The study examined how safe the treatment was, how well it worked to control lupus symptoms, and how the body's immune cells responded over time. Participants were monitored to track the medication's effects and any side effects that might occur.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
Australia
France
Germany